KZIA · KAZIA THERAPEUTICS LTD

NasdaqHealthcareBiotechnology

Kazia Therapeutics Ltd Is A Biotechnology Company Focused On Pharmaceutical Drug Development In Oncology. The Company Has A Portfolio Of Development Candidates Across Various Technologies Targeting Multiple Cancer Indications. Its Primary Program Is Paxalisib, An Investigational Brain-Penetrant Inhibitor Of The Pi3k/Akt/Mtor Pathway, Designed For The Treatment Of Brain Cancer. The Company Develops Targeted Therapies Aimed At Addressing Medical Needs In Oncology. The Company Operates In Australia And The United States.

HealthcareNasdaqAUVery Low Float

$10.25

+57.9% latest move

Price & move as of the most recent catalyst (Nov 17) — not a live quote.

FLOAT

1.6M

FREE FLOAT %

12%

SHARES O/S

13.0M

MARKET CAP

$137.0M

EXCHANGE

Nasdaq

COUNTRY

KZIA Catalyst History

Regulatory and ClinicalNov 17, 2025 · 3:59pm ET

KZIAKazia Therapeutics Limited American Depositary Shares

Kazia Therapeutics Reports Initial Immune-Complete Response in TNBC Trial

Patient with Stage IV Triple-Negative Breast Cancer shows positive results.

Be early on the next KZIA spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

KZIA · KAZIA THERAPEUTICS LTD

KZIA Catalyst History

Kazia Therapeutics Reports Initial Immune-Complete Response in TNBC Trial

Kazia Therapeutics Reports Initial Immune-Complete Response in TNBC Trial

Kazia Therapeutics Launches Clinical Trial for Paxalisib and Immunotherapy in Advanced Breast Cancer

Kazia Therapeutics Launches Clinical Trial for Paxalisib and Immunotherapy in Advanced Breast Cancer